Search results
OCUL Shares Experience Decline in Value – Knox Daily
Knox Daily· 22 hours agoAs published in their initiating research note from BofA Securities on February 09, 2024, Ocular Therapeutix Inc [OCUL] has been a Buy and the price target has been revised ...
Ocular Therapeutix: Q1 Earnings Snapshot
San Francisco Chronicle· 3 days agoBEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Tuesday...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoOcular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization ...
Ocular Therapeutix stock target cut, Buy rating kept By Investing.com
Investing.com· 2 days agoOn Wednesday, H.C. Wainwright adjusted its price target on shares of Ocular Therapeutix (NASDAQ:OCUL...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 4 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 3 days agoFinancial Outlook: Cash reserves expected to support operations into 2028, providing stability for...
12 Health Care Stocks Moving In Monday's Pre-Market Session - Acutus Medical (NASDAQ:AFIB), Addex...
Benzinga· 4 days agoThe market value of their outstanding shares is at $685.9 million. NeuBase Therapeutics NBSE shares fell 16.47% to $0.34. The company's market cap stands at $1.2 million. Ocular Therapeutix ...